AcuSurgical Raises €5.75 Million in Series A Financing to Advance its Robotic Ocular Microsurgery Platform

Source: AcuSurgical

AcuSurgical, a French robotic microsurgery company, announced a €5.75 million Series A financing. Using advanced robotics, AcuSurgical aims to make ocular microsurgery safer and more accessible by improving the precision of surgical interventions. A proof of concept of the platform has been completed with a first prototype validated in a preclinical setting.

The funding will be used to conduct clinical trials with the goal of reaching regulatory approval with vitreo-retinal surgery. The financing round is led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating in the round.

Retinal surgeries represent an annual global market of 1.6 million procedures, currently performed by a limited number of specialized surgeons. AcuSurgical’s robotic platform aims to increase the precision of current procedures, filtering tremor and augmenting visualization with the aid of a telemanipulated robot, while the surgeon remains in complete control.

Founded by Christoph Spuhler, serving as Chief Executive Officer, AcuSurgical has already attracted an experienced and highly skilled multidisciplinary team of executives, alongside the scientific co-founders, Prof. Yassine Haddab and Prof. Philippe Poignet, robotics experts at the joint research Unit LIRMM (Laboratory of Computer Science, Robotics and Microelectronics in Montpellier) and Prof. Philippe Gain and Prof. Gilles Thuret, retinal surgeons at the Saint-Etienne University Hospital.

“Our ambition is to enable new treatments for retinal disease that will open new perspectives for the numerous patients who are impacted by these debilitating retinal conditions. We are proud of the vote of confidence by this strong syndicate of investors. This financing will allow us to grow the team and reach key milestones towards certification and commercialisation of a truly innovative surgical solution”, Mr. Spuhler, CEO and co-founder of AcuSurgical, said in a company news release.

“We are delighted to partner with such an experienced team and look forward to supporting AcuSurgical in bringing to market a novel solution that will improve ocular surgeries and open new procedures in ophthalmology”, says Valérie Calenda, Managing Partner at Mérieux Equity Partners.


Related Content